Intravenous Zoledronate for a Patient with Paget's Disease.
10.11005/jbm.2014.21.3.223
- Author:
Ki Choul KIM
1
Author Information
1. Department of Orthopedic Surgery, Dankook University School of Medicine, Cheonan, Korea. puhoo73@hanmail.net
- Publication Type:Case Report
- Keywords:
Bone density conservation agents;
Diphosphonates;
Osteitis deformans
- MeSH:
Bone Density Conservation Agents;
Bone Resorption;
Diphosphonates;
Female;
Humans;
Middle Aged;
Osteitis Deformans;
Osteoclasts;
Osteogenesis;
Osteoporosis
- From:Journal of Bone Metabolism
2014;21(3):223-226
- CountryRepublic of Korea
- Language:English
-
Abstract:
Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for treatment of osteoporosis, have been the most effective agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate.
